Related Experiment Video
Updated: Aug 8, 2026
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor
Shozo Furumoto1, Kyoka Takashima, Kazuo Kubota
1Institute of Development, Aging and Cancer and Graduate School of Pharmaceutical Scinces, Tohoku University, Sendai, Japan. shozo@idac.tohoku.ac.jp
Nuclear Medicine and Biology
|March 8, 2003
Summary
A novel fluorine-18 labeled inhibitor, [(18)F]SAV03M, shows potent efficacy as a prodrug for matrix metalloproteinase-2 (MMP-2) imaging. This compound demonstrates enhanced tumor accumulation, making it a promising candidate for positron emission tomography (PET) tumor imaging.
Area of Science:
- Radiopharmaceutical Chemistry
- Molecular Imaging
- Oncology
Background:
- Matrix metalloproteinase-2 (MMP-2) is crucial for tumor invasion.
- Developing targeted imaging agents for MMP-2 is vital for cancer diagnostics.
Purpose of the Study:
- To evaluate the biological efficacy of [(18)F]SAV03M, a novel fluorine-18 labeled MMP-2 inhibitor prodrug.
- To assess its potential for positron emission tomography (PET) tumor imaging.
Main Methods:
- In vivo evaluation using an Ehrlich tumor-bearing mouse model.
- Biodistribution studies and radio-thin-layer chromatography for metabolite analysis.
- Whole body autoradiography to determine tissue distribution.
Main Results:
- [(18)F]SAV03M demonstrated effective conversion to the parent drug in vivo.
- The prodrug [(18)F]SAV03M showed a 2.4-fold increase in tumor uptake compared to [(18)F]SAV03.
- Tumor-specific accumulation of radioactivity was observed with [(18)F]SAV03M.
Conclusions:
- [(18)F]SAV03M is a potent prodrug of [(18)F]SAV03 with enhanced tumor targeting capabilities.
- This agent shows significant potential for effective tumor imaging using PET.
